StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Investment analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

Shares of NASDAQ:APTO opened at $0.36 on Friday. Aptose Biosciences has a 52-week low of $0.33 and a 52-week high of $3.32. The company has a market capitalization of $6.60 million, a P/E ratio of -0.06 and a beta of 1.26. The company has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.76.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the SEC. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.